Solange Peters, MD, Lausanne University Hospital, Switzerland
On-site Interpretation of the DAREON-8 Study – The Bispecific Antibody Obrixtamig Combined with Standard Therapy Brings New Momentum to First-Line Treatment for Slowly Progressing Extensive-Stage Small Cell Lung Cancer After Immunochemotherapy!